The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
Abstract
PURPOSE: This phase III study compared docetaxel and doxorubicin in patients with metastatic breast cancer who had received previous alkylating agent–containing chemotherapy. PATIENTS AND METHODS: Patients were randomized to receive an intravenous infusion of docetaxel 100 mg/m 2 or doxorubicin 75 mg/m 2 every 3 weeks for a maximum of seven treatment cycles. RESULTS: A total of 326 patients were randomized, 165 to receive doxorubicin and 161 to receive docetaxel. Overall, docetaxel produced a significantly higher rate of objective response than did doxorubicin (47.8% v 33.3%; P = .008). Docetaxel was also significantly more active than doxorubicin in patients with negative prognostic factors, such as visceral metastases (objective response, 46% v 29%) and resistance to prior chemotherapy (47% v 25%). Median time to progression was longer in the docetaxel group (26 weeks v 21 weeks; difference not significant). Median overall survival was similar in the two groups (docetaxel, 15 months; doxorubicin, 14 months). There was one death due to infection in each group, and an additional four deaths due to cardiotoxicity in the doxorubicin group. Although neutropenia was similar in both groups, febrile neutropenia and severe infection occurred more frequently in the doxorubicin group. For severe nonhematologic toxicity, the incidences of cardiac toxicity, nausea, vomiting, and stomatitis were higher among patients receiving doxorubicin, whereas diarrhea, neuropathy, fluid retention, and skin and nail changes were higher among patients receiving docetaxel. CONCLUSION: The observed differences in activity and toxicity profiles provide a basis for therapy choice and confirms the rationale for combination studies in early breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Modeling the Drop-Out Mechanism in Repeated-Measures Studies
Little, R. J. A. (1995) · Journal of the American Statistical Association · doi:10.1080/01621459.1995.10476615 · Cited by 1,522
Unbalanced Repeated-Measures Models with Structured Covariance Matrices
Jennrich, R. I., & Schluchter, M. D. (1986) · Biometrics · doi:10.2307/2530695 · Cited by 1,325
Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer
Coates, A., Gebski, V., Bishop, J. F., Jeal, P. N., Woods, R. L., Snyder, R., Tattersall, M. H. N., Byrne, M., Harvey, V., Gill, G., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712103172402 · Cited by 537
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy
Schwartz, R. G., McKenzie, W. B., Alexander, J., Sager, P., D'Souza, A., Manatunga, A., Schwartz, P. E., Berger, H. J., Setaro, J., Surkin, L., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90212-9 · Cited by 510
Osoba, D., Zee, B., Pater, J., Warr, D., Kaizer, L., & Latreille, J. (1994) · Quality of Life Research · doi:10.1007/bf00451727 · Cited by 414
Methods for the analysis of informatively censored longitudinal data
Schluchter, M. D. (1992) · Statistics in Medicine · doi:10.1002/sim.4780111408 · Cited by 287
Henderson, I. C., Allegra, J. C., Woodcock, T. M., Wolff, S., Bryan, S., Cartwright, K. J., Dukart, G., & Henry, D. W. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.560 · Cited by 246
Pérez, D. J., Harvey, V. J., Robinson, B. A., Atkinson, C. H., Dady, P. J., Kirk, A. R., Evans, B. D., & Chapman, P. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.12.2148 · Cited by 116
A Comparative Study of Doxorubicin and Epirubicin in Patients with Metastatic Breast Cancer
Hortobágyi, G. N., Yap, H. Y., Kau, S., Fraschini, G., Ewer, M. S., Chawla, S. P., & Benjamin, R. S. (1989) · American Journal of Clinical Oncology · doi:10.1097/00000421-198902000-00014 · Cited by 88
Cited by
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Self-citationBenson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Metadata
- Authors
- Chan, S., Friedrichs, K., Noel, D., Pintér, T., Van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., Yelle, L., von Minckwitz, G., Korec, S., Simmonds, P., Buzzi, F., González Mancha, R., Richardson, G., Walpole, E., Ronzoni, M., Murawsky, M., Alakl, M., Riva, A., & Crown, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-08
- Volume
- 17
- Issue
- 8
- Pages
- 2341-2341
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141056749
- Cited by
- 641
- References
- 16
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.